Alnylam Q4 net product rev $346M, FY $1.24B (+39%); FY24 guide $1.4-1.5B; HELIOS-B readout late June/early July

ALNYLAM PHARMACEUTICALS, INC.

2023-FY EPS reported -$3.52 revenue$1,828,292,000

Q4 net product revenue $346M: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.
Full year 2023 net product revenue $1.24B, up 39% YoY; GAAP net loss per share ($3.52); non-GAAP ($1.61).
FY24 guidance: combined net product revenue $1.4B-$1.5B, plus collaboration and royalty revenue; operating expense guidance provided.
HELIOS-B Phase 3 top-line results expected late June or early July; updated statistical analysis plan announced.
FDA cleared Part B of ALN-APP Phase 1 study at doses up to 180 mg every six months; partial clinical hold remains for higher doses.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ALNYLAM PHARMACEUTICALS, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue $346 Million and $1,241 Million, Respectively.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $346 Million and $1,241 Million, Respectively
Result: reported results

Exact text from the filing

Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001157523-24-000253

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.